首页> 外文期刊>Tetrahedron letters: The International Journal for the Rapid Publication of Preliminary Communications in Organic Chemistry >Molecular hybridization-guided 1,3-dipolar cycloaddition reaction enabled pyrimidine-fused spiropyrrolidine oxindoles synthesis as potential anticancer agents
【24h】

Molecular hybridization-guided 1,3-dipolar cycloaddition reaction enabled pyrimidine-fused spiropyrrolidine oxindoles synthesis as potential anticancer agents

机译:分子杂交指导的1,3-偶极环加成反应使嘧啶融合的螺吡咯烷氧并吲哚合成成为潜在的抗癌药

获取原文
获取原文并翻译 | 示例
           

摘要

Reported is a facile and efficient Methodology toward the synthesis of novel pyrimidine-fused spiropyrrolidine oxindoles via a multicomponent 1,3-dipolar cycloaddition reaction of pyrimidine-fused 3-alkenyloxindoles I with azomethine ylides (thermally generated in situ from sarcosine and formaldehyde). Products bearing adjacent quaternary-tertiary centers were smoothly obtained in high yields (up to 90% yield) with good diastereoselectivity (up to >20:1). In addition, their biological activity has been preliminarily demonstrated by in vitro evaluation against human lung cancer cells A549, human prostate cancer cells PC-3, and human leukemia cells 1<562 by the MIT-based assays, using the commercially available broad-spectrum anticancer drug of Cisplatin as a positive control. The results also demonstrated that most of the compounds showed considerable cytotoxicities to these three cell lines of 1<562, PC-3, and A549, showed comparably potent or even more potent than the positive control of Cisplatin (up to 3.0 times), and indicated that novel pyrimidine-fused spiropyrrolidine oxindoles may be potential leads for further biological screenings and may generate drug-like molecules. (C) 2016 Elsevier Ltd. All rights reserved.
机译:报道了一种通过嘧啶融合的3-链烯基氧吲哚I与偶氮甲亚胺的多组分1,3-偶极环加成反应(由肌氨酸和甲醛原位热生成)合成新型嘧啶融合的螺吡咯烷氧吲哚的简便有效的方法学。以高收率(最高90%收率)和非对映选择性好(最高> 20:1)顺利获得带有相邻四级-三级中心的产物。另外,使用基于市售的广谱光谱,通过基于MIT的分析方法,通过体外评估人肺癌细胞A549,人前列腺癌细胞PC-3和人白血病细胞1 <562,初步证明了它们的生物学活性。顺铂的抗癌药为阳性对照。结果还表明,大多数化合物对这三种1 <562,PC-3和A549细胞系均显示出相当大的细胞毒性,与顺铂的阳性对照相比具有更强的效力,甚至更高(最多3.0倍),并且指出新型嘧啶融合的螺吡咯烷恶唑可能是进一步生物学筛选的潜在线索,并可能产生类似药物的分子。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号